The chemical and biological effects of cis-dichlorodiammineplatinum (II), an antitumor agent, on DNA.
cis-Dichlorodiammineplatinum (II) binds irreversibly to the bases in DNA; the amount of platinum complex bound can be determined from changes in the ultraviolet absorption spectrum. As the ratio of platinum to phosphate is increased, an increasing inactivation of bacterial transforming DNA is observed. At a ratio that corresponds to spectrometric saturation, transforming activity is inactivated >10(5)-fold. The trans isomer of the platinum complex, which is not effective against tumors, induces a similar inactivation of transforming DNA but with half the efficiency, indicating a different mode of binding. The sensitivity to inactivation by cis isomer varies slightly with the genetic marker assayed but is not dependent on the excision repair system. Uptake of DNA by competent cells is unaffected by bound platinum complex; however, integration of platinum-bound transforming DNA into the host genome decreases as the mole fraction of platinum increases. This loss of integration parallels the decreased transforming activity of the DNA. Although the drug induces interstrand crosslinks in DNA in vitro, these crosslinks are relatively rare events and cannot account for the observed inactivation.
D002945:Cisplatin / Q000378:metabolism / Q000494:pharmacology; D004247:DNA / Q000037:antagonists & inhibitors / Q000378:metabolism; D004277:DNA, Single-Stranded; D006193:Haemophilus influenzae / Q000187:drug effects; D006358:Hot Temperature; D007536:Isomerism; D009690:Nucleic Acid Conformation; D009691:Nucleic Acid Denaturation; D010761:Phosphorus Radioisotopes; D013056:Spectrophotometry, Ultraviolet; D013329:Structure-Activity Relationship; D014170:Transformation, Genetic / Q000187:drug effects
D004277:DNA, Single-Stranded; D010761:Phosphorus Radioisotopes; D004247:DNA; D002945:Cisplatin